One blood test could screen you for 50 cancers. Here’s why it’s controversial.
The Galleri blood test failed to meet its primary objective in a study of more than 142,000 participants, though researchers noted some encouraging results. Despite this failure, an FDA advisory panel previously recommended the test for approval. The screening tool targets over 50 cancer types and costs $949. Medical experts remain divided over the test's reliability, with some warning that it could lead to increased false positives and billions in wasted spending.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The Galleri blood test screens for more than 50 types of cancer.
- ✓ An FDA advisory panel recommended the approval of the Galleri test.
What changed
A trial involving over 142,000 people revealed the Galleri test failed to achieve its main goal.
Live updates
-
Grail cancer screening test fails main goal in 142,000 person trial
The Galleri blood test failed to meet its primary objective in a study of more than 142,000 participants, though researchers noted some encouraging results. Despite this failure, an FDA advisory panel previously recommended the test for approval. The screening tool targets over 50 cancer types and costs $949. Medical experts remain divided over the test's reliability, with some warning that it could lead to increased false positives and billions in wasted spending.
Why it matters
Early detection of cancer can improve survival rates, but inaccurate screening leads to unnecessary treatments. Natera is also developing a multi-cancer test that has received FDA breakthrough status.
What is confirmed
- The Galleri blood test screens for more than 50 types of cancer.
- The test costs $949.
- An FDA advisory panel recommended the approval of the Galleri test.
Still unconfirmed
- The Galleri test failed to achieve its main goal in a trial of over 142,000 people.
- The Galleri test will waste billions of dollars and increase false positives.
What to watch next
- Final FDA regulatory decision on Galleri approval
- Clinical trial results for Natera's multi-cancer blood test
confidence 80%Sources used for this update (4)
- www.nationalgeographic.com — What Alzheimer’s Blood Tests Can’t Tell You About Your Dementia Risk
- welltica.com — A blood test promises to detect over 50 cancers early but a ...
- www.healthcaredive.com — 5 doctors weigh in on the promise, limitations of a closely ...
- dralhilali.com — Oncology videos and content | Dr AlHilali
-
FDA advisory panel recommends approval for Grail cancer screening test
An FDA advisory panel recommended the approval of Grail's Galleri blood test despite claims that the test failed its own major trial. The Galleri test screens for over 50 types of cancer and costs $949. While some patients have used the test to find rare malignancies without symptoms, critics argue the test will waste billions of dollars and increase false positives. Separately, Natera has received FDA breakthrough status for its own multi-cancer blood test, though this designation does not constitute final regulatory approval.
Why it matters
Multi-cancer early detection tests aim to identify malignancies through a single blood draw before symptoms appear. These tests face scrutiny over the risk of overtesting and the clinical validity of their trial data.
What is confirmed
- Grail's Galleri blood test screens for over 50 types of cancer.
- The Galleri test costs $949.
- FDA breakthrough status is not an approval.
Still unconfirmed
- The Galleri test would increase false positives.
What to watch next
- The final FDA decision on the approval of Grail's Galleri test
- Release of missing data for Natera's multi-cancer blood test
confidence 80%Sources used for this update (3)
- www.medicaldaily.com — Natera's Multi-Cancer Blood Test Gets FDA Breakthrough Status ...
- www.kjzz.org — A new type of blood test could detect multiple types of ...
- geneticliteracyproject.org — Viewpoint: RFK Jr.’s stacked FDA advisory council endorses ...
-
US FDA Decision on Galleri Blood Test Looms Amid Controversy
The US Food and Drug Administration is poised to decide on Grail's Galleri blood test, which screens for over 50 types of cancer. Medical experts are divided over the $949 test, citing concerns about false positives and its main trial. Some patients have detected rare malignancies without prior symptoms, while critics warn of harms tied to overtesting.
Why it matters
The Galleri test's approval would mark a significant advancement in cancer screening, but concerns about its cost, efficacy, and potential harms have sparked debate. The test's ability to detect multiple types of cancer from a single blood sample has been touted as a game-changer, but some experts argue that its benefits may be overstated. The FDA's decision will have far-reaching implications for cancer diagnosis and treatment.
What is confirmed
- Grail's Galleri blood test screens for over 50 types of cancer.
- The test costs $949.
- Medical experts are divided over the test's approval.
What to watch next
- US FDA approval decision
- Further trials on test efficacy
- Reimbursement policies for the $949 test
confidence 90%Sources used for this update (2)
- www.one.com — Domains, Hosting, Websites & Email in One Place | one.com UK
- campaign.one-line.com — ONE
-
Galleri Cancer Blood Test Awaits FDA Decision Amid Debate
Grail's Galleri blood test, which screens for over 50 types of cancer, awaits a decision from the US Food and Drug Administration following an advisory panel's recommendation for approval. Medical experts remain divided over the multi-cancer early detection screening test, citing concerns regarding its $949 cost, the risk of false positives, and whether its main trial fell short. While some patients like Valerie Caro detected rare malignancies without prior symptoms, critics warn of physical, psychological, and financial harms tied to overtesting.
Why it matters
Multi-cancer early detection blood tests represent a shifting paradigm in oncology, moving beyond single-organ screenings like mammograms. However, the medical community questions whether widespread commercial availability benefits patients before survival gains are definitively proven. Major medical associations also caution against unverified screening methods for asymptomatic individuals.
What is confirmed
- Grail's Galleri blood test screens for over 50 types of cancer in healthy individuals.
- A US Food and Drug Administration advisory panel recommended the approval of the Galleri test.
- The Galleri test costs approximately $949.
Still unconfirmed
- The main trial for the Galleri test fell short according to a screening researcher.
What to watch next
- An official US Food and Drug Administration decision regarding the approval of the Galleri cancer screening test.
- Further data on survival gains and clinical trial performance for multi-cancer early detection blood tests.
confidence 90%Sources used for this update (13)
- www.one-line.com — Global Container Shipping Solutions | ONE
- www.one-line.com — ONE : Cargo Tracking
- en.wikipedia.org — 1 - Wikipedia
- en.wikipedia.org — Ocean Network Express - Wikipedia
- www.one.com — one.com: AI Website Builder, Hosting, Domains & Email
- medicalxpress.com — Before saying yes to the medical test, know the risks and benefits
- www.medicaldaily.com — Cancer Blood Test Galleri Nears FDA Decision as Screening ...
- badgerherald.com — A new era in cancer detection: Exact Science’s Cancerguard is ...
- www.longevitybenchmark.com — Galleri Test Review (2026): Multi-Cancer Early Detection
- www.mcgill.ca — This Blood Test Screens for Cancer. Should You Vote for It?
- www.onepay.com — OnePay | Mobile banking to send, spend, borrow, build credit,...
- www.onefc.com — ONE Championship - The Home of Martial Arts
-
FDA Panel Endorses Grail Multi-Cancer Early Detection Blood Test
A US Food and Drug Administration advisory panel recommended the approval of Grail's Galleri blood test, which screens for over 50 types of cancer in healthy individuals. While the panel supports the test, medical experts and researchers remain divided. Critics point to the risk of false positives and a lack of proven survival gains for patients. The debate centers on whether the ability to detect multiple cancers outweighs the potential for physical, psychological, and financial harm caused by overtesting.
Why it matters
Early detection of cancer typically reduces late-stage diagnoses and improves patient outcomes. This test represents a first-of-a-kind approach to screening multiple malignancies from one blood draw.
What is confirmed
- An FDA advisory panel endorsed Grail's multi-cancer early detection blood test.
- The Galleri test aims to screen for more than 50 types of cancer from a single blood draw.
Still unconfirmed
- Doctors are split over the test's false positive rates and unproven survival gains.
What to watch next
- Final FDA approval decision
- Peer-reviewed data on patient survival rates
- Public funding or insurance coverage determinations
confidence 90%Sources used for this update (4)
- oncolifecentre.com — Can One Blood Test Screen for 50+ Cancers? Experts Debate
- kffhealthnews.org — Before Saying Yes to the Medical Test, Know the Risks and Benefits
- www.cherokeephoenix.org — FDA panel endorses first-of-a-kind cancer blood test from ...
- www.statnews.com — Taxpayers shouldn’t pay for an ineffective multi-cancer ...
-
FDA Panel Backs Grail's Multi-Cancer Blood Test
A US Food and Drug Administration advisory panel has endorsed Grail's multi-cancer early detection blood test, which aims to screen for over 50 types of cancer from a single blood draw. The test, called Galleri, has shown promise in detecting multiple cancer types, but its overall performance, safety, and clinical utility remain debated among medical experts. The test's ability to detect cancers at an early stage and reduce late-stage diagnoses has been highlighted in recent studies.
Why it matters
The development of a multi-cancer blood test has significant implications for cancer diagnosis and treatment. Currently, only a few cancers have routine screening tests, and most are detected after symptoms appear, making them harder to cure. A blood test that can screen for multiple cancers could potentially improve early detection and treatment outcomes. However, concerns about the test's accuracy, false positives, and clinical utility need to be addressed.
What is confirmed
- Grail's multi-cancer early detection blood test can screen for over 50 types of cancer from a single blood draw.
- The test has shown promise in detecting multiple cancer types, including at an early stage.
- The FDA advisory panel's endorsement is a significant step towards potential approval and availability of the test.
- Concerns about the test's accuracy, false positives, and clinical utility remain among medical experts.
- Recent studies, including the Pathfinder 2 trial and Mayo Clinic research, have highlighted the test's ability to detect multiple cancer types.
Still unconfirmed
- The blood test could be available to the public as early as next year.
What to watch next
- FDA approval of Grail's multi-cancer blood test
- Publication of detailed trial results and further studies on the test's performance
- Recommendations for clinical use and implementation of the test
confidence 85%Sources used for this update (13)
- www.sciencedaily.com — A simple blood test could detect multiple cancers and reveal where they started
- www.yahoo.com — FDA panel endorses first-of-a-kind cancer blood test from Grail
- www.usatoday.com — Galleri cancer blood test backed by FDA panel. Why it's ...
- www.medicalnewstoday.com — Blood test trends may predict cancer risk before nonspecific symptoms like unexplained weight loss
- www.medicaldaily.com — A Blood Test for 50 Cancers Goes Before the FDA: An ...
- www.timesnownews.com — One Blood Test To Detect Over 50 Cancers: Indian Doctors See ...
- jen.jiji.com — Tamberi: "Two weeks without competitions and I've already regained all the weight I lost"
- www.earth.com — One blood test dramatically expanded cancer detection beyond routine screening
- www.centraloregondaily.com — A controversial, cancer-detecting blood test just got backed ...
- www.yahoo.com — 'A groundbreaking finding': Multi-cancer blood test could be ...
- www.aol.com — One blood test dramatically expanded cancer detection ... - AOL
- www.yahoo.com — Bay Area biotech's groundbreaking blood test to detect 50 ...
-
FDA Advisory Panel Endorses Multi-Cancer Blood Test
An advisory panel to the Food and Drug Administration has endorsed a controversial multi-cancer early detection blood test developed by Grail. The test aims to screen for more than 50 types of cancer from a single blood draw. While recent studies including the Pathfinder 2 trial and Mayo Clinic research have highlighted the test's ability to detect multiple cancer types, the screening tool remains a subject of ongoing debate among medical experts regarding its overall performance, safety, and clinical utility.
Why it matters
Multi-cancer early detection tests represent a major shift in oncology by attempting to identify numerous malignancies before symptoms appear. Whether Medicare and other health insurers will eventually cover the screening tool hinges upon formal approval by the Food and Drug Administration. The recent committee vote serves as a crucial hurdle cleared on the path toward regulatory authorization.
What is confirmed
- An FDA advisory panel endorsed a multi-cancer early detection blood test.
- The test is designed to screen for more than 50 types of cancer.
- The screening technology was developed by Grail.
- Recent evaluations of the test include the Pathfinder 2 study and research conducted at the Mayo Clinic.
Still unconfirmed
- Future health insurance and Medicare coverage for the screening tool will depend entirely on receiving final FDA approval.
What to watch next
- Final regulatory approval decision by the Food and Drug Administration
- Decisions by Medicare and other health insurers regarding coverage for the test
confidence 100%Sources used for this update (15)
- NPR — Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote
- Nature — Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study
- Mayo Clinic News Network — Multicancer blood test detects 17 cancer types in large prospective study
- Scientific American — Blood test for multiple cancers clears crucial hurdle on track to FDA approval
- The New York Times — F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test
- seattletimes.com — FDA advisory panel endorses controversial cancer blood test
- Reuters — US FDA advisers endorse Grail cancer test's benefits in key vote
- The Washington Post — One blood test could screen you for 50 cancers. Here’s why it’s controversial.
- Cleveland 19 News — New blood test can detect more than 50 types of cancer. Here’s what to know
- Star Tribune — Cancer blood test advances toward FDA approval after Mayo research
- USA Today — A controversial, cancer-detecting blood test just got backed by key FDA panel
- WSJ — Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community